Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Rating of “Hold” by Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus recommendation of “Hold” from the twenty-five ratings firms that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $102.00.

Several research analysts have commented on ZBH shares. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, July 25th. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. Barclays lowered their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Truist Financial restated a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company decreased their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tema ETFs LLC boosted its position in shares of Zimmer Biomet by 39.8% during the 2nd quarter. Tema ETFs LLC now owns 4,194 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 1,194 shares in the last quarter. Kentucky Trust Co increased its position in Zimmer Biomet by 285.0% in the 2nd quarter. Kentucky Trust Co now owns 770 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 570 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Zimmer Biomet by 22.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 152,064 shares of the medical equipment provider’s stock worth $13,091,000 after buying an additional 28,130 shares during the period. Valeo Financial Advisors LLC raised its stake in Zimmer Biomet by 1.6% during the 2nd quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after buying an additional 175 shares during the period. Finally, Wilsey Asset Management Inc. boosted its holdings in Zimmer Biomet by 4.7% in the second quarter. Wilsey Asset Management Inc. now owns 421,867 shares of the medical equipment provider’s stock worth $36,318,000 after acquiring an additional 18,883 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.3%

Shares of NYSE ZBH opened at $94.20 on Monday. The firm has a market cap of $18.22 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 2.77 and a beta of 0.45. The company has a 50 day simple moving average of $88.84 and a 200 day simple moving average of $89.85. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.